Table 1.
Recent clinical trials concerning immune-checkpoint inhibitors in pancreatic cancer
| NCT Number | Status | Phase | Tumor types | Interventions | Monotherapy/Combination |
|---|---|---|---|---|---|
| NCT02305186 | Recruiting | Phase 1/2 | Pancreatic Cancer | Pembrolizumab + Neoadjuvant chemoradiation | Combination |
| NCT02930902 | Recruiting | Phase 1 | Pancreatic Cancer | Pembrolizumab + Paricalcitol + Surgical Resection or Pembrolizumab + Paricalcitol + Surgical Resection + Gemcitabine + Nab-pacilitaxel | Combination |
| NCT02451982 | Recruiting | Phase 1/2 | Pancreatic Cancer | Cyclophosphamide + GVAX pancreatic cancer or Cyclophosphamide + GVAX pancreatic cancer + Nivolumab | Combination |
| NCT02866383 | Recruiting | Phase 2 | Metastatic Pancreatic Cancer | Nivolumab + Ipilimumab + Radiotherapy | Combination |
| NCT03519308 | Recruiting | Early Phase 1 | Pancreatic Cancer | Nivolumab + Nab-Paclitaxel + Gemcitabine + Paricalcitol | Combination |
| NCT03404960 | Recruiting | Phase 1/2 | Pancreatic Cancer | Niraparib + Nivolumab or Niraparib + Ipilimumab | Combination |
| NCT03104439 | Recruiting | Phase 2 | Microsatellite Stable Colorectal Cancer Pancreatic Cancer MSI High Colorectal Cancer |
Nivolumab + Ipilimumab + Radiation therapy | Combination |
| NCT01473940 | Active, not recruiting | Phase 1 | Ductal Cell Adenocarcinoma of the Pancreas Recurrent Pancreatic Cancer Stage III Pancreatic Cancer Stage IV Pancreatic Cancer |
Ipilimuma + Gemcitabine hydrochloride | Combination |
| NCT01896869 | Suspended | Phase 2 | Metastatic Pancreatic Adenocarcinoma | Ipilimumab + Vaccine + FOLFIRINOX | Combination |